论文部分内容阅读
呼吸道合胞病毒(RSV)是造成世界范围内婴幼儿下呼吸道病毒性感染的主要原因之一,目前尚未研制出有效的疫苗,也没有特异性的治疗方法。被动免疫制剂能够有效预防RSV感染。静注RSV免疫球蛋白(RSV-IVIG)降低RSV易感儿童住院率,但其应用存在一定的局限性;抗RSVF蛋白的单抗Palivizumab是美国FDA批准的第一种用于传染病的人源化单克隆抗体,能够有效预防RSV感染、安全性高;其优化后的单抗Motavizumab亲和力和效力更强于Palivizumab。本文对RSV被动免疫制剂的研究进行了综述。
Respiratory syncytial virus (RSV) is one of the major causes of viral infection of the lower respiratory tract in infants and young children worldwide. No effective vaccine has been developed and there is no specific treatment. Passive immune agents can effectively prevent RSV infection. Intravenous RSV immunoglobulin (RSV-IVIG) can reduce the susceptibility of children with RSV hospital admission, but its application has some limitations; anti-RSV F protein monoclonal antibody Palivizumab is the first FDA-approved human for infectious diseases Monoclonal antibody, which can effectively prevent RSV infection, is safe and safe. The optimized monoclonal antibody Motavizumab has higher affinity and potency than Palivizumab. This article reviewed the research of passive immunization of RSV.